[SAGE] Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity |
Reward10points
Best Answer
2024-4-24
|
| |
10
Sample size and power calculation for testing treatment effect heterogeneity in cluster randomized crossover designs
10
Transparietal diffusion of polidocanol: Potential complication of sclerotherapy?
10
Pigmentation of lower limbs: Contribution of haemosiderin and melanin in chronic venous insufficiency and related disorders
10
Crash Prediction on Horizontal Curves: Review and Model Performance Comparison
10
Hip Dislocation and Subluxation in Athletes: A Systematic Review
